文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

细胞因子吸附器CytoSorb®是否降低脓毒症或脓毒性休克危重患者的万古霉素暴露?一项前瞻性观察性研究

Does the cytokine adsorber CytoSorb® reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study.
PubMed 文献 · Ann Intensive Care · 2022-05-23
一句话结论作者推荐在CytoSorb®治疗期间2小时内额外输注500 mg万古霉素,以避免亚治疗浓度。

该前瞻性观察性研究纳入7例接受连续肾脏替代治疗和CytoSorb®治疗的脓毒症或脓毒性休克危重患者,共20次CytoSorb®治疗(160份血清样本/24份在CytoSorb®治疗期间,全部为持续输注),用群体药代动力学模型量化CytoSorb®对万古霉素的清除。结果发现CytoSorb®治疗期间存在显著吸附(p < 0.0001),万古霉素清除率最大增加291%(CytoSorb®安装后初始),最大吸附容量572 mg,代表性患者AUC降低93 mg/L*24 h;CytoSorb®治疗期间2小时内额外给予500 mg万古霉素后AUC仅降低4 mg/L*24 h。作者据此推荐CytoSorb®治疗期间2小时内输注500 mg万古霉素以避免亚治疗浓度。

要点

  • CytoSorb®治疗期间万古霉素清除率最大增加291%(CytoSorb®安装后初始),最大吸附容量572 mg(p < 0.0001)。
  • 代表性患者CytoSorb®治疗期间AUC降低93 mg/L*24 h。
  • CytoSorb®治疗期间2小时内额外给予500 mg万古霉素后AUC仅降低4 mg/L*24 h。
  • 作者推荐CytoSorb®治疗期间2小时内输注500 mg万古霉素以避免亚治疗浓度。

适用人群与场景

  • 接受连续肾脏替代治疗和CytoSorb®治疗的脓毒症或脓毒性休克危重患者(前瞻性观察性研究纳入7例患者共20次CytoSorb®治疗)。

处置流程与药物剂量

  • 作者推荐CytoSorb®治疗期间2小时内输注500 mg万古霉素,以避免亚治疗浓度。

研究设计与关键结果

  • 研究类型:前瞻性观察性研究;7例患者共20次CytoSorb®治疗,160份血清样本(其中24份在CytoSorb®治疗期间),万古霉素全部为持续输注。
  • 用群体药代动力学模型描述万古霉素药代动力学:不含CytoSorb®时,经典一室模型(以连续血液透析的废液流速作为清除率的线性协变量)最佳描述实测浓度。
  • CytoSorb®治疗期间存在显著吸附,呈线性下降(p < 0.0001),万古霉素清除率最大增加291%(CytoSorb®安装后初始),最大吸附容量572 mg。
  • 代表性患者CytoSorb®治疗期间AUC降低93 mg/L*24 h。
  • CytoSorb®治疗期间2小时内额外给予500 mg万古霉素可减弱该效应,AUC仅降低4 mg/L*24 h。
  • 最终模型基于随机模拟得出给药建议。

证据类型、等级与局限

  • 证据类型:前瞻性观察性研究(样本量7例患者、20次CytoSorb®治疗)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者建议在CytoSorb®治疗期间2小时内额外输注500 mg万古霉素,以避免亚治疗浓度。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Hemadsorption of cytokines is used in critically ill patients with sepsis or septic shock. Concerns have been raised that the cytokine adsorber CytoSorb® unintentionally adsorbs vancomycin. This study aimed to quantify vancomycin elimination by CytoSorb®.

METHODS: Critically ill patients with sepsis or septic shock receiving continuous renal replacement therapy and CytoSorb® treatment during a prospective observational study were included in the analysis. Vancomycin pharmacokinetics was characterized using population pharmacokinetic modeling. Adsorption of vancomycin by the CytoSorb® was investigated as linear or saturable process. The final model was used to derive dosing recommendations based on stochastic simulations.

RESULTS: 20 CytoSorb® treatments in 7 patients (160 serum samples/24 during CytoSorb®-treatment, all continuous infusion) were included in the study. A classical one-compartment model, including effluent flow rate of the continuous hemodialysis as linear covariate on clearance, best described the measured concentrations (without CytoSorb®). Significant adsorption with a linear decrease during CytoSorb® treatment was identified (p < 0.0001) and revealed a maximum increase in vancomycin clearance of 291% (initially after CytoSorb® installation) and a maximum adsorption capacity of 572 mg. For a representative patient of our cohort a reduction of the area under the curve (AUC) by 93 mg/L*24 h during CytoSorb® treatment was observed. The additional administration of 500 mg vancomycin over 2 h during CytoSorb® attenuated the effect and revealed a negligible reduction of the AUC by 4 mg/L*24 h.

CONCLUSION: We recommend the infusion of 500 mg vancomycin over 2 h during CytoSorb® treatment to avoid subtherapeutic concentrations. Trial registration NCT03985605. Registered 14 June 2019, https://clinicaltrials.gov/ct2/show/NCT03985605.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Scharf C, Weinelt F, Schroeder I, et al. Does the cytokine adsorber CytoSorb® reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study. Ann Intensive Care. 2022. PMID: 35599248. doi:10.1186/s13613-022-01017-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。